This article is more than 5 years old. Information may no longer be current.
DNA test may be effective biomarker in breast cancer treatment
Click Here to Manage Email Alerts
Circulating tumor DNA was identified in nearly 100% of a cohort of women with metastatic breast cancer, according to study results.
The researchers noted that circulating cell-free DNA carrying tumor-specific alterations have not been investigated as thoroughly as other circulating biomarkers in breast cancer.
The current study was a comparison of radiographic images of tumors with the assay of circulating tumor DNA, cancer antigen 15-3 (CA 15-3) and circulating tumor cells.
Thirty eligible participants had metastatic disease and were receiving systemic therapy.
Twenty-nine of the 30 women (97%) with somatic genomic alterations had circulating tumor DNA. CA 15-3 was detected in 21 of 27 women (78%), whereas circulating tumor cells were detected in 26 of 30 (87%).
Circulating tumor DNA levels were associated with a greater dynamic range than the comparators. These levels also were linked to a greater correlation with changes in tumor burden than CA 15-3 or circulating tumor cells.
The earliest measure of treatment response was circulating tumor DNA, and that was observed in 10 of 19 women (53%).
“This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific and highly sensitive biomarker of metastatic breast cancer,” the researchers wrote.
Click Here to Manage Email Alerts